相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Optimization of ketone-based P2Y12 receptor antagonists as antithrombotic agents: Pharmacodynamics and receptor kinetics considerations
Fabrizio Giordanetto et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
A One-Pot Asymmetric Synthesis of a N-Acylated 4,5-Dihydropyrazole, A Key Intermediate of Thrombin Inhibitor AZD8165
Staffan Karlsson et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2014)
Oral, Direct Thrombin and Factor Xa Inhibitors: The Replacement for Warfarin, Leeches, and Pig Intestines?
Alexander Straub et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Discovery and Clinical Evaluation of 1-{N-[2-(Amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a Thrombin Inhibitor with an Oxyguanidine P1 Motif
Tianbao Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats
Susanne Pehrsson et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Design and discovery of novel, potent pyrazinone-based thrombin inhibitors with a solubilizing amino P1-P2-linker
S. Bulat et al.
LETTERS IN DRUG DESIGN & DISCOVERY (2006)
Orally active thrombin inhibitors.: Part 2:: Optimization of the P2-moiety
UEW Lange et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
J Stangier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Protease-activated receptors: Contribution to physiology and disease
VS Ossovskaya et al.
PHYSIOLOGICAL REVIEWS (2004)
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors
MB Young et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2-pyrimidylmethyl 3-(2,2-difluoro-2(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs
D Euler et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors.: Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1N-benzylamides
CS Burgey et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans
UG Eriksson et al.
DRUG METABOLISM AND DISPOSITION (2003)
Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'
PEJ Sanderson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Structure-based design of novel potent nonpeptide thrombin inhibitors
NH Hauel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection
A Kawabata et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95:: Intestinal absorption properties, biochemical and pharmacodynamic effects
D Gustafsson et al.
THROMBOSIS RESEARCH (2001)
分享论文
